Harmonization and Standardization of Panel-Based Tumor Mutational Burden (TMB) Measurement: Real-World Results and Recommendations of the QuIP Study.

This study provides real-world evidence that all evaluated panels can be used to estimate TMB in a routine diagnostic setting and identifies important parameters for reliable tissue TMB assessment that require careful control. As complex/composite biomarkers beyond TMB are likely playing an increasing role in therapy prediction, the efforts by QuIP and FoCR also delineate a general framework and blueprint for the evaluation of such assays.